BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 80.1%

Neg 0% Neu 0% Pos 80.1%

BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.

Comments

No comments yet. Be the first!